ESR1 and breast carcinoma: Of the 125 treatment-naïve, biopsy-proven breast cancers, 92 were ER+ (74%), 88 were PR+ (71%), 21 were HER2+ (17%), 111 were high proliferation with Ki-67 greater than 15% (90%).